Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Oncology is the leading therapy area for innovation - in terms of the level of clinical trial activity, number of companies investing in therapeutics, size of the pipeline of therapies in clinical development, novel active substances being launched, and the level of expenditure on these drugs. In 2021, during a global pandemic, cancer care continued to be delivered although a backlog in treatment and screenings raised worrying questions.
In a record-setting year, more novel cancer medicines became available for the first time than in any year in history, and many of them employ immunology or precision biomarkers to transform the way patients are treated. Adoption of breakthrough medicines and diagnostics is improving outcomes for millions around the world, though broad and equitable access remains a significant challenge to healthcare stakeholders — including patients.
This year’s annual report on Global Oncology Trends examines those novel medicines and the clusters of research, which promise a continuing sequence of breakthroughs in the decade to come. The report explores the impact of COVID-19 disruptions and the longer-term trends in the use of cancer medicines as well as the drivers of spending globally, in key geographies, by tumor type, and for specific types of oncology drugs.
The Quest for Evidence-Based Research in Healthcare Decision-making.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
See where IQVIA is questioning the status quo and investing in new technologies and methodologies to change how things are done.